Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
SLN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.53 - $24.38
Previous CloseN/A
Volume50.54K
Average Volume (3M)266.72K
Market Cap
$166.11M
Enterprise Value$682.83M
Total Cash (Recent Filing)£121.33M
Total Debt (Recent Filing)£117.00K
Price to Earnings (P/E)―
Beta0.56
Next Earnings
May 14, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding46,659,940
10 Day Avg. Volume180,018
30 Day Avg. Volume266,724
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.19
Price to Cash Flow (P/CF)-5.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$35.80Price Target Upside905.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Silence Therapeutics News
PremiumCompany Announcements
Silence Therapeutics Plc Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
Silence Therapeutics Reports 2024 Financial Results and Strategic Focus
PremiumCompany Announcements
Silence Therapeutics Extends Cash Runway to 2027---
Bulls Say, Bears Say
Bulls Say
Commercial OpportunityZerlasiran's ~100% Lp(a) reduction in clinic, coupled with low dosing frequency and clean safety profile can render a significant commercial opportunity.
Financial FlexibilitySilence's cash runway now extends into 2027, providing financial flexibility to advance its RNAi pipeline in rare diseases.
Regulatory ValidationZerlasiran represents a potential blockbuster opportunity, particularly with regulatory validation from the FDA (U.S.), EMA (Europe), and PMDA (Japan) on the pivotal trial design.
Bears Say
Partnership DelayThe PhIII start for the Lp(a) program is now paused until a partner is secured.
Stock WeaknessThe lack of a clear registrational trial design and the delay of a competitor catalyst from NVS/IONS have contributed to the stock weakness.
---
Ownership Overview
6.10%
Insiders
1.46% Mutual Funds
37.78% Other Institutional Investors
54.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $3.53 and its highest was $24.38 in the past 12 months.
What is Silence Therapeutics’s market cap?
Silence Therapeutics’s market cap is $166.11M.
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is May 14, 2025 which is in 51 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on Feb 27, 2025. The company reported $0.071 earnings per share for the quarter, beating the consensus estimate of -$0.219 by $0.29.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -0.15.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 46,659,940 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of $0.071 in its last earnings report, beating expectations of -$0.219. Following the earnings report the stock price went down -1.048%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Currently, no hedge funds are holding shares in SLN
---
Silence Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.80 (905.62% Upside)
$35.80 (905.62% Upside)
Blogger Sentiment
Bullish
SLN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 295.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 11.1%
Last 30 Days ▼ 11.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.31%
12-Months-Change
Fundamentals
Return on Equity
-99.23%
Trailing 12-Months
Asset Growth
90.06%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations.
---
SLN Company Deck
---
SLN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted positive clinical trial results for zerlasiran and divesiran, revenue growth, and an extended cash runway. However, the termination of the Hansoh Pharma collaboration and the delay of the zerlasiran Phase 3 study due to the need for a partner were significant challenges mentioned.Read More>---
SLN Stock 12 Month Forecast
Average Price Target
$35.80
▲(905.62% Upside)
Technical Analysis
Best Analysts Covering SLN
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-15.62%
reiterated a buy rating 25 days ago
Copying Myles Minter's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -15.62% per trade.
---